

Level 2, 66 Hunter Street  
Sydney NSW 2000  
Tel: (61-2) 9300 3344  
Fax: (61-2) 9221 6333  
E-mail: [pnightingale@biotron.com.au](mailto:pnightingale@biotron.com.au)  
Website: [www.biotron.com.au](http://www.biotron.com.au)

28 October 2013

The Manager Companies  
ASX Limited  
20 Bridge Street  
Sydney NSW 2000

(11 pages by email)


Dear Madam

**BIOTRON TO PRESENT AT AUSTRALIA BIOTECH INVEST 2013**

Biotron Limited ('Biotron') is today presenting at Australia Biotech Invest 2013 in Melbourne, Australia. The conference provides a unique opportunity to showcase the Company's product pipeline and its investment potential to an international audience of investors and potential partners.

A copy of the presentation is attached.

Yours sincerely



Peter J. Nightingale  
Company Secretary

**About Biotron and BIT225**

Biotron Limited is engaged in the research, development, and commercialisation of drugs targeting significant viral diseases with unmet medical need, with a major focus on HIV and HCV. The Company has BIT225 in clinical development for both HIV and HCV, and also has several earlier stage preclinical and research programs for several other viral infections including Dengue.

BIT225 has recorded highly encouraging data against HCV in clinical trials. A phase 2a trial in HCV demonstrated that 100% of HCV genotype 1-infected patients receiving BIT225 (400 mg) in combination with current standard of care therapies interferon and ribavirin had undetectable virus after 48 weeks.

BIT225 is also in development for treatment of HIV, and is the first in a new class of antiviral drugs that may provide a new approach to eradication of this virus. It has shown clinical efficacy against HIV in reservoir cells, and has the potential to be combined with new or existing anti-retroviral drugs to eradicate long-lived pools of virus that are not eliminated with current treatments.

A further phase 2 trial, 3 month-dosing trial of BIT225 in HCV genotype 1 and 3-infected patients is anticipated to commence in late 2013.

**BIOTRON LIMITED (ASX:BIT)**

# **Clinical Stage Antiviral Drug Development Company**

**Michelle Miller**

**CEO & Managing Director**

**+61 (0) 412 313 329**

**[mmiller@biotron.com.au](mailto:mmiller@biotron.com.au)**

***Biotron***



# Forward Looking Statements

This presentation may contain forward-looking statements with respect to the financial condition, results and business achievements/performance of Biotron Limited and certain of the plans and objectives of its management. These statements are statements that are not historical facts. Words such as “should”, “expects”, “anticipates”, “estimates”, “believes” or similar expressions, as they relate to Biotron Limited, are intended to identify forward-looking statements. By their nature, forward-looking statements involve risk and uncertainty because they reflect Biotron’s current expectations and assumptions as to future events and circumstances that may not prove accurate. There is no guarantee that the expected events, trends or results will actually occur. Any changes in such assumptions or expectations could cause actual results to differ materially from current expectations.






# Biotron Limited Overview

- Clinical stage antiviral drug development company
  - Clinical programs for Hepatitis C virus (HCV) and HIV
  - Earlier stage programs include Dengue and others
  - Spun out from Australian National University, Canberra, Australia
  - Headquartered in Sydney, Australia
  - IPO Jan 2001 (ASX:BIT)
- ***Key recent highlights***
  - ***Oct 2013 – HIV/HCV: Announced positive interim 12-week data from Phase 2 trial***
  - ***July 2013 – HIV/HCV: Completed Phase 2 trial recruitment***
  - ***Mar 2013 – HIV: Announced positive preliminary headline results from Phase 2a trial***
  - ***Nov 2012 – HCV: Announced positive 48-week follow-up data from Phase 2a trial***

***Biotron***




# Biotron - Advanced Pipeline of Clinical Programs

INDICATION	VIRAL TARGET	DISCOVERY	PRECLINICAL	PHASE 1a	PHASE 1b	PHASE 2a	PHASE 2b	STATUS
Hep C	p7							<ul style="list-style-type: none"> <li>Ph 2a complete;</li> <li>Ph 2b (3 mth dosing) scheduled for 4Q13</li> </ul>
HIV	Vpu							<ul style="list-style-type: none"> <li>Ph 2a complete</li> </ul>
HIV/Hep C	Vpu/p7							<ul style="list-style-type: none"> <li>Ph 2 completed clinical phase</li> </ul>
Next generation - HCV	p7							<ul style="list-style-type: none"> <li>Ready for IND-enabling (formal preclinical) studies</li> </ul>
Dengue	M							

*Biotron*



# BIT225 – New Class of HCV DAA Drug



- ✓ Novel, oral, small molecule compound
- ✓ Only one of its class (p7 inhibitor) in clinical trials
- ✓ Inhibits viral assembly; active at later stage of virus life cycle to polymerase and protease inhibitors
- ✓ Doesn't readily generate resistance
- ✓ Clinically active against hard-to-treat HCV genotype 1 (1a and 1b) and genotype 3
- ✓ Also active against HIV hiding in reservoir cells

**“Hepatitis C market is forecast to grow by 230% peaking at \$15.5bn in 2022”**

Source: Datamonitor Healthcare

*Biotron*

# BIT225 – Proven Clinical Activity Against HCV

BIT225	Interferon + Ribavirin	BIT225-005
Placebo		

0                      4 wks                      12 wks                      //                      48 wks


Treatment	12 WEEKS	48 WEEKS
	Early Virological Response*	Sustained Virological Response*
400 mg BIT225 + IFN/RBV	86%	100%
200 mg BIT225 + IFN/RBV	88%	88%
Placebo + IFN/RBV	63%	75%

*\*virus levels below limit of detection i.e. 50 IU/ml*

**Clear demonstration that BIT225 has good antiviral activity in hard-to-treat, treatment-naïve HCV genotype 1 patients**

*Biotron*

# BIT225 – HIV / HCV Co-Infected Trial




- **Phase 2 HIV/HCV trial - completed clinical phase in July 2013**
  - ~30% of HIV-infected people in the USA are also HCV-infected
  - Significantly worse prognosis than mono-infected patients
  - Genotypes 1 and 3; 28 days dosing in combination with IFN/RBV
  - Treatment-naïve to HCV treatment with RBV and/or IFN; virologically suppressed on HIV drugs (ART)
  - ***Interim 12-week data demonstrated that 100% of HCV genotype 3 patients were clear of virus and that BIT225 enhances effect of IFN/RBV in HIV/HCV co-infected patients***

**BIT225 is uniquely placed due to dual anti-HIV and anti-HCV activity**



# BIT225 – Proven Clinical Activity Against HIV

- Phase 1b/2a randomised, placebo controlled, double-blind trial
  - 24 patients, HIV-1 positive, treatment-naïve
  - 10 days dosing with BIT225 (monotherapy)
- Results demonstrated that:
  1. BIT225 significantly reduces HIV levels in the macrophage (reservoir) cells in HIV-infected subjects
  2. BIT225 can cross the blood-brain barrier, opening up the possibility of treatment of AIDS-related dementia



**Results support a potential role for BIT225 in cure/eradication strategies**

# BIT225 –Multiple Market Opportunities

- **Hepatitis C**

- Potential for future combination cocktails with polymerase and protease inhibitors
  - Unique mode of action
  - Good drug-drug interaction profile
  - Limited alternative classes for combinations (prevention of resistance)
  - Potential to fill gaps left by other DAA classes
- Add-on to IFN/RBV treatment ex-USA

- **HIV/HCV**

- Part of combination cocktail with either IFN/RBV and/or other new DAAs

- **HIV**

- Add-on to anti-retroviral treatment to clean out underlying reservoirs
- Part of future eradication or cure strategies



# Key Financials and Facts

## KEY FINANCIALS

ASX Code	BIT
Recent Share Price (24 Oct 2013)	A\$0.10
52 Week High	A\$0.15
52 Week Low	A\$0.08
Shares on Issue	228 million
Market Capitalization	A\$23 m
Net Cash (30 Sept '13)	A\$3.5 m

## BOARD AND MANAGEMENT

Mr Michael Hoy	Chairman
Dr Michelle Miller	CEO & Managing Director
Dr Denis Wade	Non-Executive Director
Dr Susan Pond	Non-Executive Director
Mr Robert Thomas	Non-Executive Director
Mr Bruce Hundertmark	Non-Executive Director
Mr Peter Nightingale	CFO & Company Secretary



**Biotron**